Cardizem LA Articles
China Sky One has 11 generics in pipeline
21 July 2008
KV's fiscal 3rd-qtr net revenue jumps 39%
17 March 2008
Andrx' 4th-qtr 2005 income drops 16%
27 March 2006
Tanabe's turnover up 1.3% by 3rd-qtr 2005
20 February 2006
Tanabe sees 1% sales dip in fiscal half-year
5 December 2005
Non-pharma business hits Tanabe's 3rd-qtr
21 February 2005
Bama-Geve sees 2005 sales up 13% in Spain
14 February 2005
Danger from same brand names for different drugs
7 February 2005
Biovail launches Tiazac XC in Canada
31 January 2005
Tanabe profit falls but still up on forecast
22 November 2004
KV resolves a handful of legal matters
20 September 2004
Biovail revises full-year outlook on robust sales
20 September 2004
Biovail's Tiazac XC cleared in Canada
23 August 2004
Tanabe sees net drop 37.7% in FY 1st qtr
16 August 2004
4th-qtr net loss near doubles at DOV Pharma
22 March 2004
Teva comments on Biovail dispute
8 March 2004
Tanabe reports above-target 9-mth earnings
1 March 2004
FDA panel wants more safety data on CV Therapeutics Ranexa
15 December 2003
Biovail files for new use of Cardizem LA
14 July 2003
Tanabe reports modest growth, misses targets
26 May 2003
B-MS settles US FTC/states
17 March 2003
B-MS settles US FTC/states
17 March 2003
Fournier forecasts growth in Singapore
17 March 2003
Aventis and Andrx to pay $80M in Cardizem settlement
3 February 2003
Biovail closer to Cardizem XL launch
24 June 2002
US seniors group joins generics lawsuits
10 June 2002
US business, govs seek Hatch-Waxman reform
13 May 2002
Strong quarter for Canada's Biovail
6 May 2002
Biovail's 2001 revenues jump 89%, EPS up 57%
4 March 2002
US FTC probes Orange Book patent listings
14 January 2002
Lower earnings expected at Andrx
14 January 2002
Forest to sell Sankyo's Benicar
13 December 2001
Aventis, Andrx charged with conspiracy
16 November 2001
US states sue Abbott, Geneva and IVAX
2 October 2001
Aventis and Watson settle over Dilacor
28 September 2001
Biovail files Cardizem XL NDA with FDA
29 August 2001
US consumer groups demand Tiazac patent withdrawal
22 August 2001
Faulding sales rise 17.5%, boosted by pharma
9 August 2001
US health plans sue Aventis and Andrx
6 August 2001
US House votes more support for generics
27 July 2001
France's Ethypharm postpones IPO
4 July 2001
France's Ethypharm announces listing
8 June 2001
Aventis, Andrx charged with conspiracy
15 May 2001
Aventis, Biovail drop lawsuit
18 January 2001
Stock Commentary - Tokyo
11 January 2001
Biovail acquires Cardizem rights from Aventis
4 January 2001
Recordati licenses lercanidipine to Forest in USA
8 November 2000
Spanish drugmakers adapt to advent of generics regime
15 September 2000
Faulding full-year sales rise 16%
6 September 2000
Ca blockers vs diuretics, "no clear benefit"
1 August 2000
"Greed vs need" in US brand/generic deals
26 July 2000
Pharma sales push Aventis' turnover up
3 May 2000
Sanofi-Synthelabo sales push $1.3 billion
26 April 2000
Aventis and Andrx charged by US FTC
22 March 2000
Faulding first-half 1999 sales up 16.6%
22 March 2000
Biovail once-daily diltiazem cleared
8 March 2000
Copaxone pushes Teva FY profits up 39.3%
16 February 2000
Andrx dispells reports of FTC investigation
10 February 2000
Aventis sales rise 4.2% in 1999
3 February 2000
HMR boosting profits at Hoechst
8 November 1999
Sanofi-Synthelabo sales up 9% in 3rd quarter
1 November 1999
Aventis integration proceeding on track; new logo launched
27 October 1999
Hoechst, Andrx to be hit by FTC lawsuit?
11 October 1999
FH Faulding earnings climb 37.6%
9 September 1999
Sanofi-Synthelabo 1st-half profits up 18%
1 September 1999
HMR helps soften blow as Hoechst profits slide
5 August 1999
HMR settles Cardizem CD suit with Andrx
16 June 1999
Synthelabo full-year sales increase 7.1%
19 January 1999
Sanofi-Synthelabo Merger Strong In Cardio, CNS
10 December 1998
Income Redefinition Helps Hoechst Marion Roussel
20 November 1998
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
